MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
I-PfSPZ-C meets in Senegal
The International PfSPZ Consortium (I-PfSPZ-C) held its semi-annual meeting in Dakar, Senegal on April 19, 2018. More than 40 Investigators from over 20 organizations in over 10 countries attended and presented the status and results of ongoing and recently completed, but unpublished, clinical trials of Sanaria® PfSPZ Vaccine, PfSPZ-CVac and PfSPZ Challenge worldwide.
Sanaria’s Executive VP Process Development and Manufacturing wins Visionary Leadership Award
Frost & Sullivan’s Manufacturing Leadership (ML) Council announces the world-class manufacturing companies and individual leaders set to receive recognition as winners of the 2018 Manufacturing Leadership Awards. ML Awards winners and their partners will be honored on June 13, 2018, at a gala celebration that concludes the 14th annual Manufacturing Leadership Summit in Huntington Beach, Calif.
New film, Hope for Bioko, showcases Sanaria’s work
Fifteen years of malaria control on Bioko Island, initially by Medical Care Development International and later Sanaria Inc., represents one of the most progressive and successful Corporate Social Responsibility projects in the Global Health arena. The CSR partners in this program include Marathon Oil, Noble Energy, Equatorial Guinea Liquefied Natural Gas and Atlantic Methanol, and the important public sector financing and involvement has come from the Government of Equatorial Guinea.
International PfSPZ Consortium Annual Meeting
The International PfSPZ Consortium (I-PfSPZ-C) held its semi-annual meeting at the University of Maryland School of Medicine in Baltimore on 9th and 10th November. This meeting saw record attendance of malaria researchers associated with Sanaria's PfSPZ program with 145 attendees from 44 institutions in 14 countries present in the room and more people joining online from around the world.
Sanaria’s malaria vaccines clinical and manufacturing progress highlighted at International meetings in Baltimore
Building upon publication of clinical trial results in Nature, PNAS, Lancet Infectious Diseases, and JCI Insight in 2017, Sanaria Inc. is highlighting the work of its many collaborators at a symposium entitled “Moving Toward a PfSPZ Malaria Vaccine for Protecting Travelers and Use in Elimination Campaigns” (session 133) at the 66th meeting of the American Society of Tropical Medicine and Hygiene in Baltimore, and then at the second 2017 International PfSPZ Consortium meeting held at the University of Maryland School of Medicine.
Advancing Global Health through Development and Clinical Trials Partnerships
The American Journal of Tropical Medicine and Hygiene publishes article, Advancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoites Vaccine for Malaria in Healthy Equatoguinean Men.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.